Araştırma Makalesi
BibTex RIS Kaynak Göster

Saf Duktal Karsinoma İn situ’lu Hastalarda Adjuvan Radyoterapi Etkinliğinin Farklı Değişkenlere Göre Değerlendirilmesi

Yıl 2021, , 369 - 374, 01.11.2021
https://doi.org/10.17517/ksutfd.828771

Öz

Introduction: Ductal carcinoma in situ is a non-invasive pathology of breast cancer. Pure ductal carcinoma in situ is extremely rare, although it is often accompanied by invasive breast cancers.
Materials and Methods:The study included 27 patients who applied to the Adana City Training and Research Hospital Radiation Oncology outpatient clinic and received adjuvant radiotherapy with a diagnosis of pure ductal carcinoma in situ.
Results:The mean age of the patients was 45.33 in the premenopausal period and 59.83 in the postmenopausal period, and a statistically significant result was obtained when the age of both groups was compared (p = 0.001). Age and tumor diameter (38.8%) was assessed statistically significant (p <0.05). it can be stated that the tumor diameter tends to increase with increasing age.
Conclusion: Age, tumor size, receptor status, operation margin, histopathological grade, multifocality and adjuvant treatments are effective on local recurrens and survival in ductal carcinoma in situ patients. Patients diagnosed with ductal carcinoma in situ receive adjuvant radiotheray after breast conserving surgery, reducing the risk of local recurrens.

Kaynakça

  • 1. Groen EJ, Elshof LH, Visser LL. Finding the balance between over- and under-treatment of ductalcarcinoma in situ (DCIS). The Breast 2017;31:274-28.
  • 2. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ. WHO Classification of Tumours of the Breast, Fourth Edition. Lyon: IARC Press; 2012. 2.

Evaluation of Adjuvant Radiotherapy Efficacy in Pure Ductal Carcinoma In situ Patients According to Different Variables

Yıl 2021, , 369 - 374, 01.11.2021
https://doi.org/10.17517/ksutfd.828771

Öz

Introduction: Ductal carcinoma in situ is a non-invasive pathology of breast cancer. Pure ductal carcinoma in situ is extremely rare, although it is often accompanied by invasive breast cancers.
Materials and Methods:The study included 27 patients who applied to the Adana City Training and Research Hospital Radiation Oncology outpatient clinic and received adjuvant radiotherapy with a diagnosis of pure ductal carcinoma in situ.
Results:The mean age of the patients was 45.33 in the premenopausal period and 59.83 in the postmenopausal period, and a statistically significant result was obtained when the age of both groups was compared (p = 0.001). Age and tumor diameter (38.8%) was assessed statistically significant (p <0.05). it can be stated that the tumor diameter tends to increase with increasing age.
Conclusion: Age, tumor size, receptor status, operation margin, histopathological grade, multifocality and adjuvant treatments are effective on local recurrens and survival in ductal carcinoma in situ patients. Patients diagnosed with ductal carcinoma in situ receive adjuvant radiotheray after breast conserving surgery, reducing the risk of local recurrens.

Kaynakça

  • 1. Groen EJ, Elshof LH, Visser LL. Finding the balance between over- and under-treatment of ductalcarcinoma in situ (DCIS). The Breast 2017;31:274-28.
  • 2. Lakhani SR, Ellis IO, Schnitt SJ, Tan PH, Van de Vijver MJ. WHO Classification of Tumours of the Breast, Fourth Edition. Lyon: IARC Press; 2012. 2.
Toplam 2 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Sağlık Kurumları Yönetimi
Bölüm Araştırma Makaleleri
Yazarlar

Feryal Karaca 0000-0002-1474-1382

Selahattin Menteş 0000-0002-1371-7356

Timuçin Çil 0000-0002-5033-1479

Sıddık Keskin 0000-0001-9355-6558

Yayımlanma Tarihi 1 Kasım 2021
Gönderilme Tarihi 20 Kasım 2020
Kabul Tarihi 17 Ocak 2021
Yayımlandığı Sayı Yıl 2021

Kaynak Göster

AMA Karaca F, Menteş S, Çil T, Keskin S. Evaluation of Adjuvant Radiotherapy Efficacy in Pure Ductal Carcinoma In situ Patients According to Different Variables. KSÜ Tıp Fak Der. Kasım 2021;16(3):369-374. doi:10.17517/ksutfd.828771